Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.

Alexander Mm EggermontMichal KicinskiChristian U BlankMario MandalaGeorgina V LongVictoria AtkinsonStéphane DalleAndrew HaydonAndrey MeshcheryakovAdnan KhattakMatteo S CarlinoShahneen SandhuJames LarkinSusana PuigPaolo A AsciertoPiotr RutkowskiDirk SchadendorfMarye Boers-SonderenAnna Maria Di GiacomoAlfonsus Jm van den EertweghJean-Jacques GrobRalf GutzmerRahima JamalAlexander C J van AkkooiPaul LoriganDmitri GrebennikClemens KreplereSandrine MarreaudStefan SuciuCaroline Robert

Published in: European journal of cancer (Oxford, England : 1990) (2024)

The 7-year analysis of adjuvant therapy with pembrolizumab demonstrated a sustained improvement in the long-term RFS, DMFS and PRFS2 compared with placebo in patients with resected stage III melanoma.

Keyphrases

phase iii
phase ii
advanced non small cell lung cancer
double blind
clinical trial
open label
skin cancer
early stage
placebo controlled
study protocol
basal cell carcinoma
randomized controlled trial
epidermal growth factor receptor
prognostic factors
tyrosine kinase